Conceptus, Inc. (CPTS) Begins Clinical Trial With Next-Generation Essure(R) to Provide Immediate Contraception  
7/10/2012 9:58:05 AM

MOUNTAIN VIEW, Calif., July 9, 2012 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the EssureĀ® procedure, the leading non-surgical permanent birth control method, today announced that it has begun patient enrollment in a 60-patient clinical trial at two medical centers in Canada and Mexico with its next-generation Essure device. The new Essure device is designed to offer not only all the advantages of the current Essure procedure, but also immediate, permanent contraception without a three-month waiting period or 90-day confirmation test.